eClinical Solutions for the Pharmaceutical Industry
Joe Eazor, CEO
Waqar Nasim, CFO
Chairman of the Board
ERT's systems are widely used by pharmaceutical and biotech companies innovating drug and device therapies to optimize clinical trial management, and to document safety and efficacy clinical outcomes data. ERT's solutions increase the accuracy and reliability of patient data and improve widely deployed solutions in healthcare areas such as Cardiac Safety, Respiratory Solutions and electronic Clinical Outcome Assessments (eCOA).
Since its inception in 1972, ERT has developed from a technology start-up to a company that today supports the conduct of thousands of clinical trials annually. This is achieved through the compilation of a variety of clinical outcome data from more than 5 million patients, in strict accordance with the standards defined by the major regulatory agencies.
In 2021, ERT merged with Bioclinica, a technological and scientific leader in clinical imaging. This combination creates a global leader in clinical trial endpoint technology and a leading partner to pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, and digital innovation with a strong focus on customer service.
Nordic Capital Fund VIII acquired ERT in 2016. In 2020, Nordic Capital, re-invested alongside Astorg and Novo through Fund IX. Building on ERT's leading technology platform and reputation for operational excellence, the new broadened ownership group, together with management, will invest in the continued development of the business with the aim of further expanding operational capabilities and selectively pursuing add-on investments to support future growth.
Tech & Payments
EUR 410 million
Nordic Capital Fund IX, co-controlling shareholding
Philadelphia, Pennsylvania, USA